Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci198418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Madhurima Ghosh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, NIH Office of the Director.
Abstract (Originalsprache)
EGFR-mutant lung adenocarcinomas (LUADs) that are vulnerable to the EGFR antagonist osimertinib (Osi) eventually relapse, owing in part to the emergence of drug-tolerant persister (DTP) cells that arise through epigenetic mechanisms. Intratumoral DTP cells can herald a worse clinical outcome, but the way in which DTP cells influence LUAD progression remains unclear. Osi-resistant (OR) cells exhibit typical DTP cell features, including a propensity to undergo senescence and epithelial-mesenchymal transition (EMT), which can activate heightened secretory states. Therefore, we postulated that OR cells influence LUAD progression through paracrine mechanisms. To test this hypothesis, we utilized congenic pairs of EGFR-mutant LUAD cell lines in which drug-naive (DN) cells were rendered OR by chronic exposure to escalating doses of Osi. Cocultured in vitro or coinjected into mice, paracrine signals from OR cells enhanced the growth and metastatic properties of DN cells. EMT and senescence activated nonoverlapping secretomes, and OR cells governed DN cells by undergoing EMT but not senescence. Mechanistically, Osi rapidly increased TGF-β2 levels to initiate EMT, which triggered a Golgi remodeling process that accelerated the biogenesis and anterograde trafficking of secretory vesicles. The protumorigenic activity of OR cells was diminished by depletion of EMT-dependent secreted proteins or the EMT-activating transcription factor ZEB1. These findings identify paracrine mechanisms by which OR cells drive LUAD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
- Section of Hematology and Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
- Tulane Cancer Center, Louisiana Cancer Research Center, New Orleans, Louisiana, USA.
- Department of Toxicology and Cancer Biology, The University of Kentucky, Lexington, Kentucky, USA.
- Department of Biosciences, Rice University, Houston, Texas, USA.
- Department of Chemistry, Texas A&M University, College Station, Texas, USA.
Förderung
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- NIH Office of the Director
- CPRIT
Zitieren
APA
Ghosh, M., Wu, C., Kumar, A., Nilsson, M., Heymach, J. V., Zhao, W., Yu, J., Liu, X., Ding, N., Wang, S., Xiao, G. Y., Chen, A., Grimley, K., Russell, W. K., Creighton, C. J., Tan, X., & Kurie, J. M. (2026). Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression. Journal of Clinical Investigation. https://doi.org/10.1172/jci198418
Vancouver
Ghosh M, Wu C, Kumar A, Nilsson M, Heymach JV, Zhao W, et al. Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression. Journal of Clinical Investigation. 2026. doi:10.1172/jci198418
BibTeX
@article{Ghosh2026,
author = {Ghosh, Madhurima and Wu, Chao and Kumar, Abhishek and Nilsson, Monique and Heymach, John V and Zhao, Weina and Yu, Jiang and Liu, Xin and Ding, Na and Wang, Shike and Xiao, Guan-Yu and Chen, Angelo and Grimley, Kate and Russell, William K and Creighton, Chad J and Tan, Xiaochao and Kurie, Jonathan M},
title = {Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci198418}
}
EUVIMED